Prognostic importance of defibrillator shocks in patients with heart failure

New England Journal of Medicine

Volumn 359, Issue 10, 2008, Pages 1009-1017

  Poole, Jeanne E ^a,l   Johnson, George W ^b   Hellkamp, Anne S ^c   Anderson, Jill ^b   Callans, David J ^d   Raitt, Merritt H ^e   Reddy, Ramakota K ^f   Marchlinski, Francis E ^d   Yee, Raymond ^g   Guarnieri, Thomas ^h   Talajic, Mario ⁱ   Wilber, David J ^j   Fishbein, Daniel P ^a   Packer, Douglas L ^k   Mark, Daniel B ^c   Lee, Kerry L ^c   Bardy, Gust H ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Seattle Institute for Cardiac Research   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Oregon Cardiology PC   (United States)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; PLACEBO;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE COURSE; FEMALE; FOLLOW UP; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 50949090502     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa071098     Document Type: Article

References (20)

1. Bardy GH, Lee KL, Mark DB, Poole JE, Fishbein DP, SCD-HeFT Investigators. Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT). In: Woosley RL, Singh SN, eds. Arrhythmia treatment and therapy. New York: Marcel Dekker, 2000:323-42.
2. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. [Erratum, N Engl J Med 2005;352:2146.]
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
4. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:2085-105.
5. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-5.
6. Cox DR. Regression models and lifetables. J R Stat Soc [B] 1972;34:187-220.
7. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 1989;64:651-4.
8. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005;26:1303-8.
9. Benza RL, Tallaj JA, Felker GM, et al. The impact of arrhythmias in acute heart failure. J Card Fail 2004;10:279-84.
10. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004.
11. Tokano T, Bach D, Chang J, et al. The effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol 1998;9:791-7.
12. Xie J, Weil MH, Sun S, et al. Highenergy defibrillation increases the severity of postresuscitation myocardial dysfunction. Circulation 1997;96:683-8.
13. Tang W, Weil MH, Sun S, et al. The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function. J Am Coll Cardiol 1999;34:815-22.
14. Yamaguchi H, Weil M, Tang W, Kamohara T, Jin X, Bisera J. Myocardial dysfunction after electrical defibrillation. Resuscitation 2002;54:289-96.
15. Weaver WD, Cobb LA, Copass MK, Hallstrom AP. Ventricular defibrillation - a comparative trial using 175-J and 320-J shocks. N Engl J Med 1982;307:1101-6.
16. Hasdemir C, Shah N, Rao AP, et al. Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks. J Cardiovasc Electrophysiol 2002;13:144-50.
17. Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2006;113:2810-7.
18. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-65.
19. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004;110:2591-6.
20. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004;15:1002-9.